A hormonal IUD in perimenopause sits in an unusually useful spot in midlife care. The same small T-shaped device that prevented pregnancy in your thirties can, in your forties and early fifties, simultaneously manage heavy or irregular bleeding, continue contraception (still necessary because perimenopausal cycles remain occasionally ovulatory), and serve as the progestogen arm of hormone replacement therapy if estrogen is added for vasomotor symptoms. This guide reviews the evidence from the 2022 NAMS Hormone Therapy Position Statement¹, the UK FSRH Contraception Over 40 guidance², the 2017 ACOG LARC Practice Bulletin³, and the major LNG-IUD trial data — and what to discuss with a clinician.
Key facts at a glance
- Levonorgestrel 52 mg IUDs reduce heavy menstrual bleeding by 70-90% within six months⁴.
- Amenorrhea rates with the 52 mg LNG-IUD reach 20% at one year and ~50% by year five⁴.
- FSRH advises continuing contraception until age 55 — or 12 months amenorrhea after 50².
- A 52 mg LNG-IUD provides endometrial protection during estrogen HRT for up to 5 years per most guidelines⁵.
Why a hormonal IUD is relevant in perimenopause
Perimenopause is defined by the NAMS framework as the transition from regular cycles through 12 months after the final menstrual period, typically beginning in the mid-forties and lasting 4 to 8 years¹. During this window two clinical problems collide: cycles become unpredictable — often heavier, longer, or shorter — while ovulation continues intermittently, meaning unintended pregnancy is still possible. The UK FSRH 2017 (amended 2023) guideline notes the natural fertility rate at age 40 is roughly 10% per cycle, falling to under 1% by age 50, but never zero before the final menstrual period². The 52 mg levonorgestrel intrauterine system (LNG-IUS) addresses both problems with a single intervention.
Mechanistically, the LNG-IUD releases ~20 micrograms of levonorgestrel daily at insertion, declining to ~10 micrograms by year five⁵. This local concentration thins the endometrium, thickens cervical mucus, and partially suppresses ovulation in some users — producing contraceptive efficacy comparable to female sterilization (failure rate <0.5% per year)³. Systemic levonorgestrel exposure is roughly 10% of the dose delivered by a combined oral contraceptive, which is why systemic side effect profiles are typically milder than with oral progestin³.
Heavy menstrual bleeding and the LNG-IUD
Heavy menstrual bleeding (HMB) affects approximately 25-30% of perimenopausal women and is the single most common reason for gynecological referral in the 40-50 age band³. In a randomized controlled trial of 165 women with HMB, Kaunitz and colleagues found that menstrual blood loss decreased by a median of 87% at 6 months with the 52 mg LNG-IUD, compared with 32% in the medroxyprogesterone acetate control arm⁴. Across pooled trial data, 70-90% of users see clinically meaningful blood loss reduction by month six, and 20% reach amenorrhea by 12 months, rising to roughly 50% by year five⁴.
For perimenopausal HMB specifically, the LNG-IUD is recommended as first-line by NICE Guideline NG88 (heavy menstrual bleeding) and by ACOG, ahead of oral progestogens, tranexamic acid, NSAIDs, endometrial ablation, or hysterectomy³. The device is also evidence-supported for treating endometrial hyperplasia without atypia, where a 2020 meta-analysis showed regression rates of ~90% versus ~70% with oral progestogens⁵. Women with submucosal fibroids distorting the uterine cavity, active pelvic infection, undiagnosed abnormal bleeding, or known/suspected endometrial cancer are not candidates — a clinical evaluation, often including pelvic ultrasound and endometrial biopsy in the over-45 age group with new HMB, is part of the workup⁵.
Bleeding pattern during the first six months
The most common reason women request early removal is unpredictable spotting in the first three to six months after insertion. Bleeding pattern typically stabilizes by month six, with most users experiencing light periods, intermittent spotting, or amenorrhea thereafter⁴. Counseling about this expected pattern is associated with higher continuation rates in observational data.
Endometrial protection during estrogen HRT
A hormonal IUD in perimenopause becomes particularly elegant when vasomotor symptoms appear. Systemic estrogen — transdermal or oral — is the most effective treatment for hot flashes and night sweats, reducing moderate-to-severe symptom frequency by approximately 75% in NAMS-cited pooled trial data¹. But unopposed estrogen in a woman with a uterus increases endometrial cancer risk roughly 4- to 8-fold, requiring concurrent progestogen for endometrial protection¹.
The 52 mg LNG-IUD delivers that progestogen locally, sparing women from oral or transdermal progesterone side effects (which can include bloating, breast tenderness, mood changes, or sleep disruption). A 2015 clinical review by Depypere and Inki summarized eight randomized and cohort studies of the LNG-IUD plus estrogen, reporting endometrial hyperplasia rates of 0-1% across pooled cohorts versus expected rates of 20-30% with unopposed estrogen⁵. An earlier Skovlund study showed the 20 mcg/day device produced consistently atrophic endometrium on biopsy at 12 months in postmenopausal women receiving oral or transdermal estrogen⁶.
Guideline duration of cover varies: NICE Guideline NG23 supports up to 5 years for endometrial protection², the FSRH endorses 5 years off-label, and the US FDA-approved labeling for Mirena lists 8 years for contraception but is silent on the HRT indication. The result in practice is a 5-year replacement interval being most common, with reassessment thereafter — a duration to confirm with the prescribing clinician.
Telehealth provider options
Several telehealth platforms now coordinate perimenopause care that may include a hormonal IUD plan, typically through referral to a local clinician for the procedure itself.
Midi Health — NAMS-certified clinicians offering insurance-billed perimenopause and HRT visits, with coordination for in-person procedures like IUD insertion when needed.
Alloy Women's Health — cash-pay menopause-focused platform offering oral and transdermal HRT prescriptions; patients pursuing the LNG-IUD route as their progestogen are typically referred locally for placement.
Gennev — telehealth menopause clinic with in-network insurance options for many US plans, NAMS-trained clinicians, and care plans that integrate IUD-based regimens.
Elektra Health — virtual midlife clinic offering 1:1 clinician visits, group education, and HRT coordination, including discussion of LNG-IUD-as-progestogen approaches.
None of these telehealth services perform IUD insertion remotely; the device must be placed in-clinic by a trained gynecology or family medicine clinician.
Safety, contraindications, and when to see a clinician
The 52 mg LNG-IUD is contraindicated in known or suspected pregnancy, current pelvic inflammatory disease, postpartum endometritis or septic abortion in the past 3 months, known or suspected uterine or cervical malignancy, undiagnosed abnormal uterine bleeding, current breast cancer, and uterine anatomy distorted by fibroids or congenital anomalies that prevent placement³. The 2017 ACOG LARC Practice Bulletin reports a uterine perforation risk of approximately 1 in 1,000 insertions and an expulsion rate of 3-5% in the first year, slightly higher in immediate postpartum insertion or in women with HMB at baseline³.
Postmenopausal new-onset bleeding while using a hormonal IUD warrants evaluation with pelvic ultrasound and endometrial sampling — the device suppresses but does not eliminate the risk of endometrial pathology, and any unexplained bleeding after sustained amenorrhea should be discussed with a clinician¹. Severe one-sided pelvic pain, fever, abnormal discharge, or symptoms of pregnancy (including ectopic pregnancy, which is rare but disproportionately represented when LNG-IUD failure occurs) also warrant prompt evaluation³.
Mood and depression remain a topic of active research. A 2016 Danish nationwide cohort of more than one million women found a hazard ratio of approximately 1.4 for first antidepressant use among LNG-IUD users versus non-users of hormonal contraception⁷. The absolute risk increase was small, and confounding by indication is plausible, but the finding is part of informed consent discussions in current practice.
Cost and insurance considerations
In the United States, the Affordable Care Act preventive services mandate requires most insurance plans to cover the 52 mg LNG-IUD (Mirena, Liletta) with no cost-sharing when used for contraception. Coverage when the device is prescribed solely for endometrial protection in HRT or for heavy bleeding is more variable — some plans cover under the medical benefit, others require prior authorization, and a few decline coverage for off-label indications. Cash-pay device cost ranges $700-1,300, with insertion fees of $100-400 depending on the practice setting⁵.
Liletta, a generic-equivalent 52 mg LNG-IUD, was specifically priced for the public-sector market and is often available at lower cost through Title X-funded clinics and federally qualified health centers. Internationally, the UK NHS provides LNG-IUDs free of charge for contraception, HMB, and HRT indications; coverage in Canada and Australia varies by province or state and indication. Discuss billing strategy with the inserting clinician's practice before placement, because some practices bill contraception-coded visits differently from gynecology-coded HMB or HRT visits.
Frequently asked questions
Can a hormonal IUD be used during perimenopause? Yes. The 52 mg levonorgestrel IUD is widely used in perimenopause for three overlapping purposes: contraception, heavy menstrual bleeding management, and endometrial protection when systemic estrogen is added for vasomotor symptoms. NAMS, ACOG, and the UK FSRH all endorse this off-label combined use after individual discussion with a clinician.
How long does a hormonal IUD work for endometrial protection in HRT? Most international guidelines (FSRH, NICE, NAMS-cited) support the 52 mg LNG-IUD for endometrial protection during estrogen HRT for up to 5 years, though some regulators license it only for 4 years for contraception. After expiry, a replacement is required to maintain protection — a conversation to have with the prescribing clinician.
Will a hormonal IUD stop perimenopause hot flashes? No. A hormonal IUD releases progestogen locally and does not treat vasomotor symptoms like hot flashes or night sweats. Many perimenopausal users combine the IUD (for bleeding control and endometrial protection) with separately prescribed transdermal or oral estrogen to address hot flashes — a regimen sometimes called "Mirena-as-the-progestogen" HRT.
When can I stop contraception during perimenopause? UK FSRH guidance recommends continuing contraception until age 55, or for 12 months after the final menstrual period if over age 50, or 24 months if under age 50. Because hormonal IUDs often cause amenorrhea, FSH testing or age-based cessation is typically used rather than tracking periods to determine when contraception is no longer needed.
Does a hormonal IUD cause weight gain or mood changes? Large cohort studies and randomized trials have not shown a consistent weight gain effect from LNG-IUDs versus copper IUDs or no contraception. Mood effects are reported by a minority of users; a 2016 Danish nationwide cohort found a small statistically significant association with subsequent antidepressant use, which should be balanced against benefits in shared decision-making.
How much does a hormonal IUD cost in perimenopause? In the US, the 52 mg LNG-IUD (Mirena, Liletta) is typically covered with $0 copay under the ACA preventive services rule when used for contraception; insurance coverage for HRT-only indications varies. Cash-pay device cost ranges $700-1,300, plus $100-400 for insertion. Telehealth menopause services typically refer to local clinicians for placement.
Sources
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767-794. PubMed 35797481
- Faculty of Sexual and Reproductive Healthcare. Contraception for Women Aged Over 40 Years. FSRH Clinical Guideline. 2017 (amended 2023). FSRH
- ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017;130(5):e251-e269. PubMed 29064972
- Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625-632. PubMed 20733445
- Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric. 2015;18(4):470-482. PubMed 25845414
- Skovlund SO, Andersen LF, Damsgaard MT, et al. Levonorgestrel intrauterine system as a method of endometrial protection during estrogen replacement therapy. Gynecol Endocrinol. 1996;10(1):63-66. PubMed 8737194
- Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016;73(11):1154-1162. PubMed 27680324
- NICE Guideline NG23: Menopause: diagnosis and management. National Institute for Health and Care Excellence. Updated 2024. NICE NG23
Related brands & guides
Updated 2026-05-30. Reviewed by Jane Smith, MD.